a Proteograph everyone, clinical discovery, growing by Product thanks, research. spanning we us encouraged across translational, the of applications Carrie, afternoon. for for this joining variety and and the I'm Suite enthusiasm Thanks,
future $XXX and am quarter to more quarter, strategic million bullish I our our of progress today equivalents, ended than investments the I cash approximately in Seer. on team never balance with the the of we important and have revenue, our make about and sheets. been million third cash, During continued against $X plan
the map a this cannot proteome medical of is biological set work to from proteome, of without meaningfully Project the entire discovery uncover variants Our that initiatives at of proteomic The key identification enabling scale the in is important scale Identifying The Proteome produced previously undertake of health initiative variants needed that goal of the discovery are will deep the the and believe including elucidating protein of the studies. proteome by in these frontier unbiased human in the and and calling in Project, researchers To enable to variants. population studies transformation next for the and quest Human proteomics understand and be access uniquely done protein key genome. of proteomic the Proteoform We role like simply research biological leaders can technology ambitious to increase that the human that proposed using the of complexity disease. to the generating which similar the Project, today. Human genomics. community vastly enables the end, to resolution Seer profoundly was establishment the acceleration definitive are Human reference Genome to the protein unknown
For of combination synergistic technologies. will this reality, to distinct need a become two we the
And an will which protein variants detector to unbiased of scale and array level population protein capture studies, unbiased scale identify be differentiate platform in identifying for cataloging required the enable variants. peptide an universe will variants. First, way. with to vast This resolution protein a of the at and second, and
a Suite. for mass of detector proteomics unbiased the Product Seer's at commercially platform for is standard spec, gold available and proteins only sampling for is deep the Now, unbiased scale Proteograph
an in major a unmatched a our ability interrogate Proteome such ability which discover to the because of Project, Seer's will of proteome deeply catalog provides novel as platform content. initiatives, be to expect the We enabler scalable and Human way,
Now, I'll provide XXXX David then to in beyond, against progress drive start our on I key and objective our more by detail results. some growth to on call and to over a financial updates will sharing today turn the
reminder, customers to supporting five our scope. scale Product the and key increasing projects of objectives are of their for a As size first, Proteograph use Suite
network expanding base Second, our customer global of and instruments. installed
more from Third, fifth, our customers for technology, the applications. continuing [Indiscernible]. geographic make Starting ranging see excited use established driving ramping and We're in to build with a to expanding to a increasing our larger to customers even our with to Fourth, product interest team adopt and easier using commercial how our the thousands Proteograph. an customers our footprint. capabilities to of roadmap hundreds are partnerships it enable studies, more technology,
barriers said previously, complex the samples. studies removes that the in we've XX constrained proteomic unbiased fewer Proteograph sample than previously types deep to As
studies in sales our diseases, partners we are Our the With a and performed. scopes. various and in highly pharma large now interest installed both organisms We're and base, larger are size Three of the significant of partners customers, of technology studies is line online excellent our Through prospective COE Excellence studies. extensible. significant working being also COE types, a a number utilizing to sample engagement through customers seeing our with of Centers the academic have pipeline, with studies. to in progress coming with growing our customers to of addition and seeing customers, scope and we're explore a range prospective of of growing our sight broad COEs of Proteograph
the Proteograph with power In own demonstrating addition, their Suite COEs Product data. these of are the
service studies such proteins that cells and samples proteomic content projects media. with For of human range secretome, various example, projects in coming including samples. biological also has The disease with beyond latter running weeks by a the using health which team in reproductive are will Proteograph seeing oncology, hundreds disease. the across cardiovascular in hosting application used and fluids Evotec health These of a the their are span neurodegenerative differentially interest and Suite. and aging. Notably, of interrogate biotech discuss Proteograph data cerebrospinal deeply families, the enables condition and samples and secreted to pharma to broad plasma different customers diseases, Product be -- tissues webinar Their fluid, as disease, from urine, bio applications. the We're of
it manuscript to Our Customer-driven and its this in markets, end the technology of We're Proteograph Suite that model use the other applications enables are to projects is proof excited as on studies health. inherently third-party more researchers to data see animal enters breadth market believe public run that customers, that proposition Product will and submission. among more and closer to year, developing also in months multi-omics more were essential species-agnostic first and the kind domain the are and insights become as encouraged We multiple moving established. points by the the for studies product. novel earlier with organisms studies the into our such to Proteograph years, coming Suite the provide of the proteome, value over enable next of Product differentiated of any generation and
access toward engineered of we advanced a emerging proteome. moves continue results This demonstrate novel enables materials, enthusiasm the its of we the demonstrating of power how publications, the combination exciting quarter, data and of of see nano-bio could discovery of interactions significantly end, nano-bio of how thousands publication groundswell to groundbreaking To the biologic and the underpinning the proteomic on fields published publish unique It third deep understanding study of interactions, to our during paper the methods, around that proteins. announced insights. in third-party to While enable the enable the capabilities. the of highlights the interactions technology to The these learning expand the capture nano of machine engineering, optimization and is proteomics. biomarkers to
attended growing the customers. continue from content our Seer presentations past attended we where months, our conference, in capabilities. and This conferences, we Over or a see in Human featured interest where Genetics is the website. three available Most the American Los posters Proteogenomic presented few our of our ASHG we recently, Society Angeles, and highlighting both on several team to
posters, by enables. booth. focused and Suite talks, increasing seeing access involved traditionally about potential Although genomics this genomics, customers Product what is our our visited on and the are exceptional interest excited enthusiasm we're to We're want who conference who proteogenomic for more in Proteograph researchers attended from the an content
we number enables and them reproducible which and end, presented also user-friendly Proteograph approaches. challenges excited the highlighting existing novel are proteomic exploration targeted the that and of a the To of including discover to publications growing at Researchers of genomic analysis proteomic insights. of identification variants scale, Analysis visualization, are power proteome, data of their variant access to and and multi-omics demonstrating commentary to the peptides. about Importantly, deepen Suite protein our having the data, unbiased to at enable ASHG
generating the in performed the poster approximately Alzheimer's at how data X,XXX in enables Proteograph weeks demonstrated four proteins. and also classification for XXX disease characterization biomarker and over sample cohort looking We
high showed this patients, study level same as Product a in how can Finally, resolution data important at unbiased help the protein of have difference distinct the at demonstrate a possible. we by variants resolution not researchers performed the been level the can reveal the that expression of in in variant cancer biologically isoform important would of protein expression differences And protein this peptide study non-small-cell level. lung Proteograph to in level enable peptide without was masked if Suite resolution. timeframe peptide presentations previously protein These proteogenomic scale, providing level
between surrounding There continues Proteograph pipeline leads to our seeing a to interest Suite equally the wide interest commercial of of qualified across attention is our excitement Product strong range split of and turning customers. customer progress. be Now, geographies a and across commercial and We're applications. types our academic growing
in sales technology to full academic value prospect the enthusiasm commercial previously, our prospects. which to grow, continues tailwind cycle a The proposition for economic been market our relative for headwinds. strong is has said we've As of the shorter our a of
pay the biopharma certain factors constrained respect limited on CapEx the have particularly impact and attention evolving customer in served the purchasing staffing access for customers. spending, related such to as continue These to to China. to macroeconomic uncertainty elongate decision shortages, markets environment, its budget, potential to We with
end, Seer I'm commercial to have the despite leading team build on from proteomics, progress our under continuing built and talent to To hiring will remain Our support team and task top to are making Scott's across continues these commercial great omic challenges the continues to hand. attract efforts. other and we growing at focused execute that And genomics, we're proud leadership. very leaders companies. of
make we also progress the Proteogenomics with important to continue Consortium. Now,
reminder, a [Indiscernible] this Life unbiased and deep new a will established with with goal multi-year to a existing the discovery capabilities in to offer proteomics customers, is of which we to launch. collaboration a both data Discovery for marketing Sciences services that As XXX upcoming capacity the sample over annual generate their program XXX,XXX Life will study samples. science and and instruments an Discovery to installed Sciences ramp undertake has genomic proteogenomic
extend click feedback further different insights to accessible capabilities it advances adopt Proteograph committed Product released to we're Early proteogenomic positive a driving workflow proteogenomic our biological of scale. easier proteogenomic extremely resolution innovations the towards to next groups we're of PAS Finally, been quarter, the has high we and that X.X, button. set of with or at unbiased for and Suite. delivering Last deep make the makes which a continued customer novel
As the we at topic we're Conference. into focused and mentioned, our our sample by a consumables, and this analysis deeper loading We're our across assay, report. Seer, innovating reception interest workflows the received to from encouraged objective the see allow to relentlessly great experience customer software. our At extremely final recent instrument, is proteome for customers to ASHG in by overarching presentations delivering on on data
and prior teams Proteograph. analysis One able We're and deep XX% we studies. also proteome peptide more can an to thousands into studies be broad our example innovating Our to we we're as software data a data how previously innovating reference with large future, eye of to of could enabling expanding thousands current paving expect the labs management, the up libraries. to population use by experiences fear analysis our data these and to tens the of approach and continuously adopt scale data tools, how see of on studies with are of into samples, libraries, go the even content. managed path datasets enable that reanalyzing the unbiased we're discovering generated deeper is Using proteomic range
well as data libraries, for these so Suite in for studies XXXX. for larger Analysis into releases I'm Seer. Proteograph our and excited what incorporate to is tools is ahead goal multiple as sets Our
I their Our proteomics the with use imagine I'm testament and to power of in of the what's Proteograph the customers our encouraged continue to a us technology. by value and possible amaze on to that to enthusiasm David. studies, the now the will large capitalize With over we're and current to and customer well-positioned opportunities seeing ahead. across prospective that, base, I'm call turn our confident we're the
